This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

AZD6765 for Treatment Resistant Depression

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: June 25, 2007
Last updated: January 20, 2011
Last verified: January 2011
The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.

Condition Intervention Phase
Depression Drug: AZD6765 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Multi-Center, Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess the Antidepressant Effect and Onset of Effect of AZD6765 in Treatment-Resistant Major Depressive Disorder Patients

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The primary objective is to determine whether an antidepressant effect can be achieved in patients with Treatment Resistant Depression determined by a change from baseline in the MADRS total score. [ Time Frame: Change from Baseline ]

Secondary Outcome Measures:
  • The secondary objective is to assess the safety and tolerability of AZD6765 as assessed by vital signs, physical examination, clinical laboratory evaluations, ECG's and incidence of adverse events. [ Time Frame: each visit; change from baseline ]

Enrollment: 34
Study Start Date: July 2007
Study Completion Date: November 2007
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AZD6765
    intravenous infusion

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Depression
  • Inadequate response to an adequate course of antidepressants

Exclusion Criteria:

  • Psychiatric disorder other than depression
  • Pregnancy or lactation
  • Current diagnosis of cancer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00491686

United States, California
Research Site
Glendale, California, United States
United States, Connecticut
Research Site
Hartford, Connecticut, United States
Research Site
New Haven, Connecticut, United States
United States, Kansas
Research Site
Wichita, Kansas, United States
United States, Maryland
Research Site
Rockville, Maryland, United States
Sponsors and Collaborators
Study Director: Mark Smith, MD, PhD AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Mark A. Smith, MD - Emerging Psychiatry Medical Science Director, AstraZeneca Identifier: NCT00491686     History of Changes
Other Study ID Numbers: D6702C00001
Study First Received: June 25, 2007
Last Updated: January 20, 2011

Keywords provided by AstraZeneca:
Long-term depression

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders processed this record on June 23, 2017